Many complex biological programs are controlled at the level of gene transcription by DNA binding transcription factors. Recent studies have revealed a novel mode of regulation by coactivator proteins, best illustrated by the PGC-1 family of coactivators. These factors are highly responsive to a variety of environmental cues, from temperature to nutritional status to physical activity, and they coordinately regulate metabolic pathways and biological processes in a tissue-specific manner. Notably, the PGC-1 coactivators play a critical role in the maintenance of glucose, lipid, and energy homeostasis and are likely involved in the pathogenic conditions such as obesity, diabetes, neurodegeneration, and cardiomyopathy. These actions also raise new opportunities for the development of novel therapeutics.
Transcription factors function through the docking of specific DHDYCQ (Lin et al., 2002a) , that are present in all family members. To date, no clear PGC-1 homolog has been found in coactivator or corepressor proteins. While transcription factors bind to DNA in a sequence-specific fashion, they generally lack lower eukaryotes including worm, fly, and yeast. The PGC-1 coactivators have powerful transcriptional activthe enzymatic activities necessary to modify chromatin, unwind DNA, and recruit RNA polymerase II. These biochemical ity when linked to a heterologous DNA binding domain Lin et al., 2002a; Puigserver et al., 1998) , or when activities are the job of coregulators, which usually exist as multiprotein complexes in the nucleus, and can be recruited to they dock on a transcription factor. While they have not been found to encode any histone acetyltransferase (HAT) activities transcription factors in response to cellular signals. Until recently, most studies of biological processes controlled at the in their primary sequence, they bind several powerful HAT-containing proteins at their N-terminal regions, including CBP, transcriptional level have focused on changes in the amounts or activities of transcription factors. While this is undoubtedly p300, and SRC-1 (Puigserver et al., 1999) . These proteins acetylate histones and remodel chromatin structure to allow access a major mode of regulation, it has become very clear that transcriptional coactivator proteins can be highly regulated and of additional factors for gene activation ( Figure 1B ). In addition, several proteins encompassing the mediator complex (also can, in fact, be the primary targets of hormonal control and signal transduction pathways (Spiegelman and Heinrich, 2004) .
known as the TRAP/DRIP complex) dock in the C-terminal region of PGC-1α (Wallberg et al., 2003) . This region also harbors Perhaps the best examples of this are the PGC-1 (PPARγ coactivator-1) coactivators. While these proteins were not the first a Ser/Arg-rich domain and an RNA binding domain and has been shown to couple pre-mRNA splicing with transcription coactivators shown to be highly regulated, their regulation and biological function have been studied in greatest detail. In fact, (Monsalve et al., 2000) . The PGC-1α transcriptional activator complex is able to displace repressor proteins, such as histone the PGC-1 family of coactivators has emerged as major players that integrate signaling pathways in the control of cellular and deacetylase and small heterodimer partner (SHP), on its target promoters, leading to augmented gene transcription (Borgius systemic metabolism. The role of the PGC-1 coactivators in the regulation of mitochondrial oxidative metabolism and the Guan et al., 2005) . A critical aspect of the PGC-1 coactivators is that they are maintenance of glucose, lipid, and energy homeostasis will be discussed in this review.
highly versatile and have the ability to interact with many different transcription factors (Table 1) ; in doing so, they activate The first member of the PGC-1 family was identified as a PPARγ-interacting protein from brown fat and is now termed distinct biological programs in different tissues. PGC-1α, for example, can bind to and coactivate most members of the PGC-1α (Puigserver et al., 1998) . PGC-1β is the closest homolog of PGC-1α and shares extensive sequence identity (Kressnuclear receptor family-often in a ligand-dependent manner (such as the ER) but sometimes without the addition of a liler et al., 2002; Lin et al., 2002a) , clustered in several distinct domains ( Figures 1A and 1B) , including an N-terminal activagand, such as with PPARγ (Puigserver and Spiegelman, 2003) . PGC-1 also targets transcription factors outside of the nuclear tion domain (40%), a central regulatory domain (35%), and a C-terminal RNA binding domain (48%). PGC-related coactivareceptor superfamily, such as SREBP (Lin et al., 2005) , FOXO1 Sox9 (Kawakami et al., 2005) . tor (PRC) has more limited homology (Andersson and Scarpulla, 2001) , including the activation domain and RNA Table 1 summarizes transcription factor targets of PGC-1α and β and their respective roles in mediating certain aspects of binding domain. Sequence analysis reveals that the PGC-1 family of coactivators is conserved in many chordate species, PGC-1 function. Many of these proteins dock in a central region between the N-terminal activation domain and the C-terincluding primates, rodents, ruminants, birds, amphibians, and fishes ( Figure 2 ). These coactivators have similar domain strucminal SR and RNA binding domains. In addition, PGC-1α has three functional LXXLL motifs that are used for the binding of ture and several signature motifs, most notably TPPTTPP and the GenBank database are aligned using the Clustal program. The relative dis-A) Sequence homology of PGC-1α, PGC-1β, and PRC. Note that activation dotance represents the degree of sequence identity among different members. Note main (red), Arg/Ser-rich domain (yellow), and RNA binding domain (purple) are that the absence of certain members in some species is likely due to the lack of present in all three PGC-1 family members. PGC-1α and PGC-1β share an addifull-length cDNA sequences in available databases. tional domain of similarity in the central region. B) Protein complexes associated with PGC-1α. PGC-1α binds to the HAT and TRAP/DRIP/Mediator complexes at the amino and carboxyl termini, respectively. SirT1 and p160 bind to the repression domain, which also contains three p38 MAP kinase phosphorylation sites. LXXLL and LLXXL denote nuclear receptor by PGC-1α and β of mitochondrial genes encoded by the two binding sites. genomes leads to increased enzymatic capacity for fatty-acid β-oxidation, Krebs cycle, and oxidative phosphorylation (OXPHOS). Importantly, PGC-1α and β also induce the expression of genes involved in heme biosynthesis, ion transport, many nuclear receptors Puigserver et al., mitochondrial translation, and protein import and can stimulate 1998). The fact that PGC-1α and β contain distinct binding mitochondrial biogenesis and increased respiratory function sites for different transcription factors raises the interesting Wu et al., 1999) . These two coactivators possibility that alleles can be made experimentally, or may exstimulate the biogenesis of mitochondria with different metaist naturally, that can carry out only a subset of functions that bolic characteristics, reflecting the fact that they regulate the the full-length proteins can stimulate. In fact, both PGC-1α and expression of overlapping but distinct sets of mitochondrial β mRNAs are alternatively spliced to generate multiple isogenes. For example, respiration stimulated by PGC-1β is more forms, though the functional significance of this remains unhighly coupled than that induced by PGC-1α, when they are known (Baar et al., 2002; Kamei et al., 2003; Meirhaeghe et expressed in differentiated C2C12 myotubes ). 2003 . Thus, modulating the relative activity of PGC-1α and β within the cell may lead to fine-tuning of mitochondrial function Regulation of mitochondrial oxidative in response to specific metabolic needs. metabolism by PGC-1
Recent studies in PGC-1α-deficient mice reveal that alOf the transcription factors that PGC-1α and β coactivate, one though this coactivator is dispensable for mitochondrial biosubset draws special attention; this includes NRF-1 and genesis per se, it is absolutely required for the normal expres-NRF-2 (Wu et al., 1999 ) and the nuclear hormone receptors, sion of a large number of mitochondrial genes (Leone et al., such as PPARα (Vega et al., 2000) , PPARδ (Wang et al., 2003 . The mRNA level of these genes is quan-ERRα (Huss et al., 2002; Huss et al., 2004; Kamei et al., 2003;  titatively reduced in all tissues examined to date, including Mootha et al., 2004; Schreiber et al., 2004) , and TR (Zhang et skeletal muscle, heart, liver, brown fat, and brain. Interestingly, al., 2004b) (Table 1 ). All of these transcription factors directly although PGC-1β shares many of its target genes with PGCregulate the expression of certain nuclear-encoded mitochon-1α in gain-of-function analysis , it is unable to drial genes and were discussed in greater detail in two recent completely compensate for the loss of PGC-1α in the normal reviews (Kelly and Scarpulla, 2004; Puigserver and Spiegel- transcription of these genes. PGC-1β mRNA levels remain unman, 2003). NRF-1 and 2 are themselves targets of PGC-1α altered in several tissues from PGC-1α null mice. The loss of (Wu et al., 1999) and are able to stimulate the expression of PGC-1α leads to significant functional deficits in oxidative memitochondrial transcription factor A (Tfam), a mitochondrial tabolism in multiple tissues and renders mice exercise intolermatrix protein essential for the replication and transcription of ant (Leone et al., 2005) . Notably, AMP-dependent kinase is mitochondrial DNA (Clayton, 1991; Parisi and Clayton, 1991;  constitutively activated in skeletal muscle lacking PGC-1α, presumably reflecting a state of energy deficit ). Virbasius and Scarpulla, 1994) . The simultaneous stimulation These results underscore a critical role of PGC-1α in the con-1998; Tiraby et al., 2003) , hepatic gluconeogenesis and ketogenesis (Herzig et al., 2001; Rhee et al., 2003 ; Yoon et al., trol of mitochondrial OXPHOS and cellular energy homeostasis. Whether a switch of energy production through enhanced 2001), and the specification of slow-twitch muscle fibers (Lin et al., 2002b) . In contrast, PGC-1β controls hepatic lipid synglycolysis occurs in PGC-1α null mice remains to be determined.
thesis and lipoprotein production (Lin et al., 2005) . It is evident that a major feature of PGC-1 function is their ability to stimulate the program of mitochondrial biogenesis while simultaTissue-specific metabolic actions of the PGC-1 coactivators neously modulating biological processes commonly associated with increased oxidative capacity for a particular tissue. As summarized in Figure 3A , PGC-1α has been shown to regulate adaptive thermogenesis in brown fat (Puigserver et al., The following sections review PGC-1 function in brown fat, A) Tissue-specific function of PGC-1α and β. PGC-1α regulates adaptive thermogenesis in brown fat, muscle-fiber specification, and hepatic-fasting response, while PGC-1β coordinates lipogenesis and lipoprotein secretion in liver in response to dietary fats. B) Regulation of PGC-1α expression in skeletal muscle and mechanisms by which PGC-1α stimulates mitochondrial gene expression. Coactivation of MEF2 by PGC-1α provides a positive feed-forward signal to rapidly induce PGC-1α expression following muscle contraction. PGC-1α induces the expression of ERRα, which activates the expression of NRF-1, NRF-2, and ERRα itself. These molecular events lead to the stimulation of nuclear-encoded mitochondrial genes. PGC-1α also simultaneously regulates the expression of slow-twitch muscle fiber genes through coactivation of MEF2.
liver, skeletal, and cardiac muscle and brain, based on gainfamilies of transcription factors, coupling triglyceride and cholesterol synthesis, lipoprotein transport, and VLDL secretion. and loss-of-function analysis in cultured cells and in vivo.
Brown fat
SREBPs are key transcription factors that control the expression of many genes that regulate fatty-acid, triglyceride (Kim PGC-1α was discovered as a molecular switch that turns on several key components of the adaptive thermogenic program and Spiegelman, 1996; Shimano et al., 1996; Tontonoz et al., 1993) , and cholesterol biosynthesis (Brown and Goldstein, in brown fat (Puigserver et al., 1998) , including the stimulation of fuel intake, mitochondrial fatty-acid oxidation, and heat 1997), while LXRs are important in the control of lipoprotein secretion. The crucial role of PGC-1β in mediating the link beproduction through expression of uncoupling protein-1 (UCP1). The expression of PGC-1α is rapidly and strongly induced by tween hyperlipidemia and saturated fat intake was demonstrated by RNAi knockdown studies in the livers of mice. Thus, cold exposure. Ectopic expression of PGC-1α is sufficient to promote differentiation toward the brown-fat lineage, as shown the PGC-1β signaling pathway provides a plausible link between consumption of saturated and trans fats and hyperlipidby activation of UCP1 expression (Puigserver et al., 1998) , even in human cells (Tiraby et al., 2003) . Notably, mice deficient emia, including hypercholesterolemia. Although the induction of PGC-1β by dietary fats is robust, in PGC-1α are extremely cold sensitive (Leone et al., 2005; . This is due to defective thermogenesis, likely the expression of most of its mitochondrial target genes is not elevated in response to fat intake. These results raise the intercaused by impaired mitochondrial programs for fatty-acid β-oxidation and electron transport, accompanied by reduced esting possibility that the activities of PGC-1β in the regulation of hepatic metabolism is strongly influenced by nutritional induction of UCP1 and deiodinase 2 in brown fat. Despite this, PGC-1α appears to be dispensable for brown adipocyte differstatus, perhaps as a result of hormonal milieu under different physiological conditions. Similarly, although PGC-1α has been entiation. One possibility is that PGC-1β, which is induced during brown-fat cell differentiation (Lin et al., 2002a) , may play a demonstrated to coactivate a large number of transcription factors in various cell types, it is highly unlikely that these pathfundamental role in the development of brown adipocytes. Liver ways are simultaneously active in the presence of PGC-1α. The molecular basis of this specificity in gene activation remains The expression of PGC-1α and β is induced in the liver at birth and in the adult liver following fasting poorly understood. It is possible that the availability of ligands and posttranslational modification of transcription factors and/ al., 2001). The transition from fed to fasted states involves drastic metabolic changes in the liver to facilitate the adaptaor the PGC-1 themselves may contribute to the promoter selectivity. This is a very important avenue for further inquiry. tion of organisms to nutrient deprivation; these changes include activation of gluconeogenesis, fatty-acid β-oxidation,
Skeletal muscle
The ability of PGC-1α to control multiple pathways in a comand the synthesis and secretion of ketone bodies. A shift in fuel usage from glucose to fats and ketone bodies by periphplex biological program is also illustrated in skeletal muscle. In this case, PGC-1α functions as a sensitive "rheostat" that eral tissues is critical for the maintenance of systemic glucose homeostasis and survival of organisms in periods of food responds to neuromuscular input and the ensuing contractile activity. The expression of PGC-1α is readily inducible by exershortage. Studies in cultured hepatocytes and in vivo have demonstrated that PGC-1α is sufficient to activate nearly all cise training in rodents and humans (Baar et al., 2002; Goto et al., 2000; Norrbom et al., 2004) . The subsequent activation of aspects of the hepatic fasting response, including gluconeogenesis, fatty-acid β-oxidation, ketogenesis, and bile-acid hocalcium signaling pathways appears to play a major role in the stimulation of PGC-1α transcription through calcineurin and meostasis. It does so by coactivating key hepatic transcription factors, such as HNF4α, PPARα, GR, FOXO1, FXR and LXR, calcium-dependent protein kinases (Wu et al., 2002) , which culminate in the activation of several transcription factors, such and directly stimulating transcription from their target promoters (Oberkofler et al., 2003; Rhee et al., as CREB and MEF2, in a feed-forward loop ( Figure 3B ) . Although AMPK has been shown to 2003; Shin et al., 2003; Zhang et al., 2004a) . In contrast to PGC-1α, PGC-1β has a minimal effect on the be required for exercise-induced PGC-1α expression (Zong et al., 2002) , the transcriptional targets of AMPK action on the expression of gluconeogenic genes, though this factor also potently enhances the expression of genes involved in fatty-acid PGC-1α promoter are still not clear. Ectopic expression of PGC-1α in myotubes stimulates oxidation and ketogenesis . The required role of PGC-1α in the control of hepatic gluconeogenesis has been GLUT4 expression and mitochondrial oxidative metabolism (Michael et al., 2001) . Importantly, transgenic expression of revealed by RNAi knockdown experiments in vivo and in genetic studies using PGC-1α knockout mice (Koo et al., 2004;  PGC-1α in fast-twitch muscle fibers at or near physiological levels leads to activation of genetic programs characteristic of . PGC-1α deficiency clearly impairs gluconeogenic gene expression and hepatic glucose production and slow-twitch muscle fibers (Lin et al., 2002b) . The skeletal muscle of these transgenic mice is resistant to contraction-induced leads to fasting hypoglycemia. In addition, mice lacking PGC-1α develop hepatic steatosis upon fasting (Leone et al., 2005) .
fatigue, indicating a functional switch of muscle fiber types by PGC-1α. Consistent with these gain-of-function studies, PGCThe physiological role of PGC-1β in the regulation of the hepatic fasting response remains under investigation.
1α-deficient skeletal muscle is prone to contraction-induced fatigue and the knockout mice are exercise intolerant (Leone Recent studies have implicated PGC-1β as a key regulator of hepatic lipogenesis and lipoprotein secretion in response to et al., 2005) . Again, PGC-1α is able to couple the metabolic and contractile arms of muscle-fiber specification and funcdietary intake of saturated fats (Lin et al., 2005) . Here, the expression of PGC-1β in the liver is strongly induced by dietary tionally transforms fast-twitch fibers into more oxidative slowtwitch fibers. It is highly likely that similar regulatory mechafats, likely through direct regulation by fatty acids in hepatocytes. PGC-1β docks and coactivates the SREBP and LXR nisms also occur in other tissues where related cell types acquire different oxidative capacities as they undergo terminal clear whether this represents the cause or the effect of the obvious brain lesions in the knockout mice. differentiation.
Transgenic expression of PGC-1β under the control of the PGC-1 and the metabolism of ROS β-actin promoter leads to mitochondrial biogenesis in skeletal
The mitochondrial electron transport chain is a major site of muscle and resistance to diet-induced obesity (Kamei et al.,
ROS production in the cell (Lenaz et al., 2002; Lowell and Shul-2003) . However, the role of PGC-1β in the control of the metaman, 2005). Under normal conditions, the balance between bolic and contractile phenotype of skeletal muscle fibers re-ROS generation and detoxification is controlled by a set of celmains to be ascertained. lular enzymes including superoxide dismutase (SOD), catalase, Heart and those involved in glutathione metabolism. As PGC-1 stimBoth PGC-1α and β are expressed very abundantly in the heart ulate mitochondrial-based respiration, they also increase the (Lin et al., 2002a; Puigserver et al., 1998) , an organ with an expression of SOD and glutathione peroxidase, as well as enextremely high and dynamic demand for ATP. Much of this supzymes responsible for glutathione biosynthesis (St-Pierre et al., ply comes from the oxidation of fatty acids, though glucose 2003). Thus, certain components of the ROS scavenging pathcan also be a substrate for mitochondrial oxidation. To date, way are linked by the PGC-1 to mitochondrial oxidative metabthe role of PGC-1β in cardiac energy metabolism is less well olism, apparently enabling cells to maintain normal redox studied, but several studies have implicated PGC-1α as a crustatus in response to changing oxidative capacity. In addition, cial regulator of oxidative metabolism in the heart. PGC-1α PGC-1α and β stimulate the expression of UCP2 and UCP3 mRNA levels are strongly induced in the neonatal heart, along St-Pierre et al., 2003; Wu et al., 1999) , with the activation of mitochondrial biogenesis and the metawhich dissipate the proton gradient and lower mitochondrial bolic switch from glycolysis to fuel oxidation in cardiac muscle membrane potential, a process thought to greatly reduce ROS (Lehman et al., 2000) . Forced expression of PGC-1α in cultured production by mitochondria (Miwa and Brand, 2003) . Hence, neonatal cardiomyocytes and in vivo powerfully stimulates the PGC-1 coactivators apparently have two related but dismitochondrial gene expression and biogenesis (Lehman et al., tinct mechanisms to modulate ROS metabolism in cells.
2000). In fact, very high transgenic expression of PGC-1α in
Reactive oxygen and nitrogen species are capable of transmouse heart leads to such robust mitochondrial biogenesis ducing cellular signals under certain conditions (Soberman, that the contractile apparatus is displaced, and dilated cardio-2003). However, excess free radical production leads to oxidamyopathy ensues. Interestingly, PGC-1α null mice develop tive stress, which causes DNA damage, lipid peroxidation, and early symptoms of heart failure, such as activation of a fetal oxidative protein modifications. It is now clear that ROS generprogram of cardiac gene expression and significant increase in ation is greatly elevated following certain metabolic perturbacirculating levels of atrial natriuretic peptide, a hallmark of tion, such as ischemia reperfusion of the heart, stroke in the cardiac dysfunction (Arany et al., 2005) . Defects in cardiac brain, as well as a wide range of disorders including neurodefunction are most clearly seen when the intact hearts were generative diseases (Ischiropoulos and Beckman, 2003) . Given studied in isolated perfusion chambers. Here, the PGC-1α-the abnormality seen in the brain and heart of PGC-1α knockdeficient heart shows a significantly lower cardiac reserve in out mice (Leone et al., 2005; , it is highly likely response to electrical or chemical stimulation (Arany et al., that the PGC-1 are important regulators of ROS metabolism 2005) and is thus less able to perform work in response to in normal physiological conditions and under certain states of increased demand. Abnormal heart rate and impaired left venoxidative stress. tricular function were also observed in PGC-1α-deficient mice following exercise (Leone et al., 2005) .
Regulation of PGC-1 activity Brain
The diverse and potent effects of PGC-1α and β on cellular PGC-1α deficiency leads to certain behavioral abnormalities, energy metabolism necessitate that their activities be tightly including profound hyperactivity (Leone et al., 2005; controlled. This, in theory, can be achieved at the transcrip-2004). These behavioral changes are associated with axonal tional and posttranscriptional levels. In fact, PGC-1α protein degeneration in the brain, especially in the striatum (Lin et al., has a very short half-life (w2.3 hr) and is greatly stabilized fol-2004), a region known to be very important in the control of lowing phosphorylation at three sites (T262, S265, and T298) movement. The molecular basis of this axonal degeneration is by p38 MAP kinase (Knutti et al., 2001; . not completely understood, though impaired energy homeoThese modifications also enhance the transcriptional activity of stasis and reactive oxygen species (ROS) metabolism due to PGC-1α by displacing p160 myb binding protein (p160
MBP
), a defects in mitochondrial function are the most likely causes. strong transcriptional suppressor (Fan et al., 2004) . The binding Neurons consume large amounts of ATP to maintain their of p160 may largely account for the suppressive activity residmembrane ionic gradient and axonal transport and rely almost ing in the central domain of PGC-1α. Additional factors that exclusively on oxidative metabolism to derive energy for this negatively impact PGC-1α action include PXR and SHP, which function. In fact, the most common symptoms of patients with interfere with PGC-1α recruitment to its target transcription genetic mutations of mitochondrial genes are neurological refactors (Bhalla et al., 2004; Borgius et al., 2002) . lated, reflecting an extremely low tolerance for perturbing Another protein that has been shown to modulate PGC-1α OXPHOS in the brain (Schon and Manfredi, 2003) . It cannot be activity is SirT1, the mammalian homolog of the yeast Sir2. ruled out, however, that PGC-1α also regulates pathways critiSirT1 associates with PGC-1α in the central regulatory region cal for neuronal function. In fact, the expression of several neubetween amino acids 200 and 400 and deacetylates PGC-1α, rofilament proteins and the α2 subunit of sodium pumps is releading to enhanced transcriptional activity in a NAD + -dependent way (Rodgers et al., 2005) . This is particularly interesting duced in the PGC-1α null brain Suwa et al., 2003; Terada et al., 2002; Zong et al., 2002) . In contrast, cyclin-dependent kinase 9 suppresses the in many species. The ability of SirT1 to bind to PGC-1α and activate it makes a direct molecular connection between the expression of PGC-1α and mitochondrial function in the heart, leading to the development of cardiomyopathy (Sano et al., pathways that impact organismal aging and metabolic regulation. An important question is whether SirT1 also modulates 2004). Intriguingly, some transcription factors that are coactivated the transcriptional activity of PGC-1β and PRC.
In addition to posttranslational mechanisms, many studies by PGC-1α can simultaneously serve as regulators of PGC-1α transcription. This is best illustrated by the regulation of PGChave clearly demonstrated that the PGC-1 coactivators are regulated at the transcriptional level in response to a variety of 1α expression by MEF2 in skeletal muscle (Czubryt et al., 2003; Handschin et al., 2003) . The presence of such autoregulatory nutritional and environmental stimuli ( Figure 3A) . PGC-1α and β are abundantly expressed in tissues with high energetic need, loops provides a molecular mechanism to sustain PGC-1α expression following physiological stimuli, as in the case of enduincluding brown fat, cardiac, and skeletal muscle and the central nervous system (Kressler et al., 2002; Lin et al., 2002a;  rance exercise (Figure 3) . Puigserver et al., 1998) . In addition, their mRNA levels are subject to substantial regulation by physiological signals within PGC-1 and metabolic diseases It is apparent now that the PGC-1 family of coactivators is these tissues. For example, PGC-1α mRNA levels are rapidly induced in brown fat following cold exposure (Puigserver et al., highly responsive to environmental stimuli and nutritional states of an organism. These coactivators transduce physio-1998) and in skeletal muscle in response to bouts of exercise (Baar et al., 2002; Goto et al., 2000) ; PGC-1β expression relogical and/or environmental signals and modulate programs of gene expression in a tissue-specific manner. The major mains unchanged under these conditions (Lin et al., 2002a) . In contrast, hepatic expression of PGC-1β is stimulated by diactivities of PGC-1α and β studied to date have been in the modulation of glucose, lipid, and energy metabolism, enabling etary-fat intake and thyroid hormone to a much greater extent than PGC-1α (Lin et al., 2005; Weitzel et al., 2003) . The expresthe organisms to adapt to their fluctuating nutritional status and environmental conditions. This adaptation to a variety of environsion of both of these coactivators is increased in the neonatal liver and heart, correlating with a dramatic expansion of oxidamental challenges, from temperature to nutritional changes to alterations in physical activity, seems to be a raison d'etre for tive capacity in these tissues during early postnatal development (Lehman et al., 2000; . PGC-1α and β the PGC-1 coactivators. Abnormal PGC-1 activities might alter metabolic properties of tissues and lead to various diseases mRNA levels are relatively low in adult liver in the fed state; however, they are readily inducible upon brief fasting (Lin et al., with underlying dysregulation of metabolism or, alternatively, allow certain cells to thrive in their unique tissue environment, 2002a; .
Although the expression of PGC-1β is not regulated by cold such as during the progression of cancer.
Since the PGC-1 coactivators regulate multiple aspects of exposure, its mRNA level is increased during differentiation of cultured brown and white adipocytes (Kamei et al., 2003; glucose, lipid, and energy metabolism, it is not surprising that dysregulation of these proteins has been observed in several et al., 2002a). While the role of PGC-1α in adaptive thermogenesis has been firmly established, the function of PGC-1β in the pathological conditions. PGC-1α mRNA levels are elevated in the liver of rodents in models of both type 1 and type 2 diaberegulation of development and function of adipocytes remains unexplored. Interestingly, the expression of PRC in cultured fites; this is likely due to alterations of the insulin/glucagons axis and hepatic insulin resistance, respectively (Herzig et al., 2001 ; broblasts is inducible by serum treatments and is regulated in a cell-cycle-dependent manner that peaks during the G 0 -to-G 1 . Increased PGC-1α activity clearly contributes to elevated hepatic glucose output and the development transition (Andersson and Scarpulla, 2001) . Thus, it is now clear that the expression of this entire family of coactivators is of hyperglycemia. In fact, acute knockdown of PGC-1α in liver improves hepatic insulin sensitivity and glucose tolerance in under control by distinct extracellular signals, consistent with the fact that they modulate different aspects of metabolism db/db mice (Koo et al., 2004) . Thus, modulating PGC-1α activity in the liver may have important implication for systemic gluand other biological processes in the cell.
Activation of the cAMP signaling pathway is a major mechacose homeostasis. PGC-1α stimulates gluconeogenic gene expression through coactivation of GR, FOXO1, and HNF4α. It nism underlying the induction of PGC-1α in several different cell types. In fact, the proximal promoter of PGC-1α contains is tempting to speculate that chemical compounds that selectively disrupt the docking of PGC-1α on these gluconeogenic a functional CREB binding site that is required for cAMP response (Herzig et al., 2001) . CREB integrates multiple signaling transcription factors may provide a novel therapeutic modality for the treatment of hyperglycemia (Barthel and Schmoll, 2003) . pathways in various cell types, including glucagon action in the fasted liver (Herzig et al., 2001) , calcium signaling through Similarly, disruption of PGC-1β docking on SREBP and LXR may specifically lead to suppression of the lipogenic and hycalcium/calmodulin-dependent protein kinase and calcineurin A in exercised skeletal muscle and heart (Handschin et al., perlipidemic activities of PGC-1β in liver. In fact, it has been demonstrated as a proof of principle that agonist ligands for 2003; Ojuka et al., 2003; Schaeffer et al., 2004) and adaptive thermogenesis in brown fat (Puigserver et al., 1998) . Stimulathe GR can be developed that promote docking of the coactivator GRIP1 to the GR while not promoting PGC-1α docking; tion of activating transcription factor 2 (ATF2) by p38 MAP kinase has also been shown to modulate the induction of PGCthese compounds have reduced hyperglycemic activity (Coghlan et al., 2003) . 1α in brown fat by cold (Cao et al., 2004) . In states of low energy, PGC-1α can also be induced by the AMP-dependent Insulin resistance is a major pathogenic factor in the devel-opment of type 2 diabetes. Recent evidence clearly points to erative disease. More importantly, the PGC-1 pathways offer novel targets for potential therapeutic intervention. It can be a strong association between insulin resistance and mitochondrial dysfunction in skeletal muscle (Lowell and Shulman, expected that the modulation of coactivator docking on their specific binding partners will provide opportunities to selec-2005). The expression of a large set of OXPHOS genes is quantitatively reduced in skeletal muscle from type 2 diabetic patively stimulate or suppress certain pathways, hence obtaining desirable physiological effects. The development of ligands for tients and insulin-resistant prediabetic individuals (Mootha et al., 2003; Patti et al., 2003) . This is accompanied by a signifinuclear receptors which can selectively recruit certain coactivators has already been demonstrated (Coghlan et al., 2003) . cant decrease in the mRNA levels of PGC-1α, PGC-1β, and NRF-1 (Patti et al., 2003) and by abnormal mitochondrial morThus, new classes of valuable drugs may be in the offing. phology (Kelley et al., 2002) . Importantly, a single nucleotide
